Zealand Pharma (ZLDPF) Stock Statistics & Valuation Metrics

Zealand Pharma has a market cap or net worth of $4.68B. The enterprise value is $9.26B.

Zealand Pharma has 71,343,800 shares outstanding. The number of shares has decreased by -2.65% in one year.

Zealand Pharma’s return on equity (ROE) is -0.13 and return on invested capital (ROIC) is -13.87%.

The current PE Ratio of Zealand Pharma is 4.5. Zealand Pharma’s PEG ratio is ―.

In the last 12 months, Zealand Pharma had revenue of 62.69M and earned -1.08B in profits. Earnings per share was -16.24.

In the last 12 months, operating cash flow was 7.54B and capital expenditures -19.02M, giving a free cash flow of 7.52B billion.

Zealand Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Zealand Pharma upcoming earnings date is Nov 13, 2025, TBA (Confirmed).

Zealand Pharma as a current ratio of 21.14, with Debt / Equity ratio of 2.54%

In the past 12 months, Zealand Pharma has paid -4.62M in taxes.

Zealand Pharma EV to EBITDA ratio is -46.67, with an EV/FCF ratio of -50.26.

Zealand Pharma has $16.58B in cash and marketable securities with $394.64M in debt, giving a net cash position of -$16.18B billion.

Gross margin is 100.06%, with operating margin of -2029.33%, and net profit margin of -1720.87%.

The average price target for Zealand Pharma is $104.89, which is 11.43% higher than the current price. The consensus rating is Strong Buy